Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02194621 · ClinicalTrials.gov registry record · Phase 4

Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria

A Phase 4 study, sponsored by Colgate Palmolive.

Completed
Registry status
Phase 4
Development phase
128
Enrollment target

NCT02194621: Completed Phase 4 study, sponsored by Colgate Palmolive.

NCT02194621 is a Phase 4 study that has completed, run by Colgate Palmolive. The registered enrollment target is 128 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02194621, a Phase 4 study, has completed, sponsored by Colgate Palmolive.

COMPLETED
Registry status
Phase 4
Development phase
128 participants
Enrollment target

Study Summary

The primary objective was to evaluate the antibacterial effects of two toothpastes containing 0.3% triclosan, 2% copolymer and 0.234% sodium fluoride in a silica base as compared to a control regular fluoride toothpaste on anaerobic and malodor bacteria 12 hours after 13 days of product use. A secondary objective was to demonstrate that a toothpaste containing 0.3% triclosan, 2% copolymer, 0.234% sodium fluoride and a flavor with odor-masking ingredients in silica base (Colgate Total Toothpaste-Flavor Option 1) provides a level of antibacterial efficacy that is "equivalent" to a toothpaste containing 0.3% triclosan, 2% copolymer, 0.234% sodium fluoride and a regular flavor in silica base (Colgate Total Toothpaste-Flavor Option 2) after 13 days of product use.

Primary Outcome

Subjects brush their teeth with assigned toothpaste 2x/day for 13 days. On clinic visit day, subjects brush their teeth and return 12 hours later for clinical evaluation. Samples of dental plaque at the gumline will be collected for microbiological analysis to determine total levels of anaerobic bacteria CFU - colony forming units.

Interventions

  • DRUG Total Flavor option 1
  • DRUG Total Flavor option 2
  • DRUG Placebo toothpaste: Crest Cavity Protection toothpaste

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2014-01
Est. Completion 2014-03
Phase Phase 4
Colgate Palmolive

51 total trials

What the finished NCT02194621 record still lists

NCT02194621 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 3 interventions - of which Total Flavor option 1 is the first listed.

NCT02194621 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02194621 about?

NCT02194621 is a clinical study titled "Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria". The primary objective was to evaluate the antibacterial effects of two toothpastes containing 0.3% triclosan, 2% copolymer and 0.234% sodium fluoride in a silica base as compared to a control regular fluoride toothpaste on anaerobic and malodor bacteria 12 hours after 13 days of product use. A secon...

What is the current status of trial NCT02194621?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 128 participants. The study started on 2014-01. Estimated completion is 2014-03.

What interventions are being tested in trial NCT02194621?

The interventions under investigation include: Total Flavor option 1 (DRUG), Total Flavor option 2 (DRUG), Placebo toothpaste: Crest Cavity Protection toothpaste (DRUG).

Who is sponsoring clinical trial NCT02194621?

This trial is sponsored by Colgate Palmolive, which has 51 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02194621's enrollment target sits among peer trials

128 634th of 2000 higher than 1,362 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02870738 · 128 participants · Phase 2

    Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

  • NCT03294460 · 128 participants · Phase 1

    Nicotinic Receptor Genetic Variation and Alcohol Reward

  • NCT04149977 · 128 participants · NA

    Blood Flow Restriction Therapy in Lower Limb Extensor Injuries

  • NCT04373057 · 128 participants · Phase 1

    Prebiotic Galacto-oligosaccharide and Acute GVHD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02194621, the US trial registry maintained by the National Library of Medicine. NCT02194621 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.